Bangladesh Class A Listing Route: No Fee and No Expiry

1. Key takeaways

Bangladesh Class A devices follow a listing route: there is no government fee, review takes about 1 month, and the certificate has no expiry date. The legal basis is §4.5 of the DGDA Medical Device Registration Guidelines — conformity assessment is the manufacturer’s own responsibility, no manufacturing licence needs to be obtained from DGDA, but DGDA must be informed through a declaration of conformity.

• Class A devices are the manufacturer’s own responsibility, per §4.5 of the DGDA Medical Device Registration Guidelines (Guidelines provision).
• No manufacturing licence needs to be obtained from DGDA for Class A (Guidelines provision).
• DGDA must be informed through a declaration of conformity (Guidelines provision).
• No government fee applies (practical estimate).
• Review takes about 1 month (practical estimate).
• The certificate has no expiry date (practical estimate).
• Application documents: a legal agreement between the manufacturer and the local agent, a letter of authorisation, the country-of-origin CFS attested by the Bangladesh Embassy, the EU declaration of conformity as a PDF, and the product catalogue; for uncommon products, one sample may be required (practical estimate).

2. Legal basis

The table below consolidates the basis for the Class A listing route. The three structural features — manufacturer self-responsibility, no manufacturing licence, and notification via declaration of conformity — are anchored in §4.5 of the DGDA Medical Device Registration Guidelines. The absence of a government fee, the roughly one-month review and the absence of an expiry date rest on registration practice, and the application document list likewise derives from practical consolidation.

3. Expert insights

Insight one: no fee does not mean no cost. What Class A waives is the government fee, but the embassy attestation fee, the local representative service fee, and the document preparation and logistics costs all remain. More importantly, Class A still requires the country-of-origin CFS attested by the Bangladesh Embassy — not a single link of the attestation chain is saved. Budgeting a Class A project at zero because the government charges nothing is a common misreading; the true cost profile shifts from official fees to authentication and representation, and those line items still need owners, timelines and funds. A realistic Class A budget therefore looks more like a Class B budget minus the government line item than like a free route, and treating it as free invites under-resourcing of exactly the activities — attestation and local representation — on which the listing depends.

Insight two: the absence of an expiry date is the greatest long-term value of the Class A route. Class B/C/D certificates must be renewed every 5 years (see the dedicated renewal article), whereas a Class A registration remains valid indefinitely once obtained. For low-risk devices with stable models, long life cycles and low update frequency, this route eliminates the entire renewal cycle and its associated costs. When portfolio decisions are made across a device family, moving truly static low-risk products into Class A listing — where the classification allows — removes a recurring regulatory workload that would otherwise repeat every five years for each product.

Insight three: even Class A may be asked for a sample. In the practical checklist, Class A requires one sample only for “uncommon products”. This point is easily overlooked: routine Class A products do not require samples, uncommon products do, and what counts as “uncommon” is judged by DGDA. The manufacturer therefore cannot fully predict in advance whether the sample obligation will be triggered, and should treat the possibility as a conditional item in the project plan rather than assume the listing process is entirely document-based. Where the sample obligation is triggered, the physical product must be produced, exported and delivered in the same way as any other physical evidence in the process, and the logistics lead time belongs on the project schedule like any other input.

4. Practical recommendations

• Advise Chinese manufacturers not to skip registration for Class A products. Some companies believe low-risk products escape DGDA scrutiny and import and sell them directly as samples or exhibition items — under the “device as drug” framework of the Drugs and Cosmetics Act, 2023, this practice falls directly into the risk zone of operating without a licence (see the dedicated article).
• The Class A route threshold is already low enough — no government fee, a short cycle, and indefinite validity — so there is no reason not to obtain the certificate.
• Prepare the declaration of conformity including the applicable standards and the product list, together with the EU declaration of conformity PDF and the product catalogue.
• Complete the Bangladesh embassy attestation of the country-of-origin CFS, since the attestation chain is not waived for Class A.
• Prepare one sample in advance for any product that might be judged uncommon, and keep the possibility flagged in the schedule.
• In the project budget, exclude the government fee but retain the embassy attestation fee and the local service fee.

5. Verification checklist

• □ It has been confirmed that the product falls into Class A
• □ The declaration of conformity has been prepared (including applicable standards and the product list)
• □ The Bangladesh embassy attestation of the country-of-origin CFS has been completed
• □ The EU declaration of conformity PDF and the product catalogue have been prepared
• □ One sample has been prepared for uncommon products
• □ The project budget excludes the government fee but retains embassy attestation and local service fees

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across South Asia, including Bangladesh. Our team prepares dossiers to DGDA expectations, manages submissions and deficiency responses, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com

Regulatory information verified as of October 27, 2026.